Endpoints News 27 mar 2026 Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate
Endpoints News 25 mar 2026 Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis' Scemblix
Endpoints News 20 mar 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 16 mar 2026 After Novartis pact, macrocycle shop Unnatural Products gets $45M Series B
Endpoints News 26 feb 2026 Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Endpoints News 18 feb 2026 Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Endpoints News 12 ene 2026 Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’s